Blood Volume Analysis as a Guide for Dry Weight Determination in Chronic Hemodialysis Patients: A Crossover Study by Malha, Line et al.
University of Kentucky
UKnowledge
Internal Medicine Faculty Publications Internal Medicine
2-11-2019
Blood Volume Analysis as a Guide for Dry Weight
Determination in Chronic Hemodialysis Patients:
A Crossover Study
Line Malha
Cornell University
Hasan Fattah
University of Kentucky, Hasan.Fattah@uky.edu
Frank Modersitzki
New York Harbor VA Healthcare System
David S. Goldfarb
New York University
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/internalmedicine_facpub
Part of the Nephrology Commons
This Article is brought to you for free and open access by the Internal Medicine at UKnowledge. It has been accepted for inclusion in Internal Medicine
Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Malha, Line; Fattah, Hasan; Modersitzki, Frank; and Goldfarb, David S., "Blood Volume Analysis as a Guide for Dry Weight
Determination in Chronic Hemodialysis Patients: A Crossover Study" (2019). Internal Medicine Faculty Publications. 191.
https://uknowledge.uky.edu/internalmedicine_facpub/191
Blood Volume Analysis as a Guide for Dry Weight Determination in Chronic Hemodialysis Patients: A Crossover
Study
Notes/Citation Information
Published in BMC Nephrology, v. 20, article no. 47, p. 1-9.
© The Author(s). 2019
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated.
Digital Object Identifier (DOI)
https://doi.org/10.1186/s12882-019-1211-7
This article is available at UKnowledge: https://uknowledge.uky.edu/internalmedicine_facpub/191
RESEARCH ARTICLE Open Access
Blood volume analysis as a guide for dry
weight determination in chronic
hemodialysis patients: a crossover study
Line Malha1, Hasan Fattah2, Frank Modersitzki3 and David S. Goldfarb4*
Abstract
Background: Volume overload and depletion both lead to high morbidity and mortality. Achieving euvolemia is a
challenge in patients with end stage kidney disease on hemodialysis (HD). Blood volume analysis (BVA) uses
radiolabeled albumin to determine intravascular blood volume (BV). The measured BV is compared to an ideal BV
(validated in healthy controls). We hypothesized that BVA could be used in HD to evaluate the adequacy of the
current clinically prescribed “estimated dry weight” (EDW) and to titrate EDW in order to improve overall volume
status. We were also interested in the reproducibility of BVA results in end stage kidney disease.
Methods: Twelve adults on chronic HD were recruited; 10 completed the study. BVA (Daxor, New York, NY, USA)
was used to measure BV at baseline. EDW was kept the same if the patient was deemed to be euvolemic by BVA
otherwise, the prescribed EDW was changed with the aim that measured BV would match ideal BV. A second BVA
measurement was done 1–3 months later in order to measure BV again.
Results: Based on BVA, 6/10 patients were euvolemic at baseline and 5/10 were euvolemic at the second
measurement. When comparing patients who had their prescribed EDW changed after the initial BVA to those who
did not, both groups had similar differences between measured and ideal BV (P = 0.75). BV values were unchanged
at the second measurement (P = 0.34) and there was no linear correlation between BV change and weight change
(r2 = 0.08).
Conclusions: This pilot study is the first longitudinal measurement of BVA in HD patients. It revealed that changing
weight did not proportionally change intravascular BV. BV remained stable for 1–3 months. BVA may not be helpful
in clinically stable HD patients but studies on patients with hemodynamic instability and uncertain volume status
are needed.
Trial registration: ClinicalTrials.gov (NCT02717533), first registered February 4, 2015.
Keywords: Volume control, Iodine radioisotopes/diagnostic use, Ultrafiltration, Volume status, Absolute blood
volume; dry weight; hemodialysis
Background
A major purpose of hemodialysis is to remove excess salt
and water and restore extracellular fluid volume (ECV)
to normal. Solute clearance has been widely used as an
objective method to assess dialysis adequacy but there is
no equivalent objective assessment for adequate and
appropriate volume status. More recently, experts have
promoted a “volume first approach”. A clear, objective
method to assess ECV would be paramount to the suc-
cess of this approach [1, 2].
Chronic volume overload is common in dialysis pa-
tients and is often unrecognized by physical exam [3, 4]
leading clinicians to overestimate dry weight and under-
estimate the ultrafiltration requirement. Prior studies
have demonstrated that in patients with end stage kid-
ney disease (ESKD), volume expansion correlates with
elevated blood pressure [5, 6] and adjusting the target
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weight leads to improved blood pressure control [7–10].
ECV overload, as determined by bioimpedance [11–14]
and lung ultrasound [15], has also been associated with
increased mortality and cardiovascular events in chronic
kidney disease.
The benefit of additional ultrafiltration and decrease in
estimated dry weight (EDW) [7], needs to be weighed
against the risks of intradialytic hypotension that can
also lead to adverse cardiovascular outcome and mortal-
ity [16–18].
There is currently no consensus about which objective
measurement of ECV may provide clinically useful and
accurate measurement of blood volume (BV) [19] to as-
sist clinicians in finding a safe middle ground between
intravascular volume depletion and deleterious ECV ex-
pansion. Blood volume analysis (BVA) using radiolabeled
albumin is often considered the gold standard to deter-
mine intravascular blood volume (BV) and allows com-
parison to an “ideal” BV [20, 21] (as detailed in the
methods section).
BVA has been used with some benefit to evaluate vol-
ume status in critically ill [22–25] as well as
non-critically ill [26] hospitalized patients. We previ-
ously demonstrated that BVA could be used successfully
in hemodialysis patients to determine BV, and changes
in BV, before and after dialysis, with good correlation
with relative BV changes as measured by the online
Crit-Line Monitor (CLM III; Hema Metrics, Kaysville,
UT, USA) [27].
More recently, Leung et al. have failed to demonstrate
a significant difference in hemodialysis outcomes (in-
cluding intradialytic hypotension) in a randomized clin-
ical trial comparing 32 patient undergoing hemodialysis
with and without relative BV monitoring [28]. The lack
of benefit from relative BV monitor thus raises the ques-
tion of the potential benefit of absolute BV measure-
ment, a more accurate indicator of intravascular volume
and thus, a more relevant monitoring technique for BV
in dialysis patients [29].
In the current study we hypothesized that BVA could
be further used in the dialysis unit to evaluate the ad-
equacy of the current clinically prescribed EDW in dialy-
sis patients and to titrate EDW in order to improve
overall volume status and decrease the incidence of
blood volume misinterpretation. In addition, we were in-
terested in the reproducibility of BVA results in HD
patients.
Methods
Patients
Eligible patients had ESKD receiving chronic, thrice
weekly hemodialysis at the New York Harbor Department
of Veterans Affairs Healthcare System (VA-NYHHS). Pa-
tients could be enrolled if they were at least 21 years old,
able to give informed consent, and willing to have two
blood volume measurements performed. We enrolled 12
eligible patients (Fig. 1) between 03/19/14 and 06/03/14.
Participants underwent post-hemodialysis BVA as a base-
line measurement. Based on their BV status, their pre-
scribed EDW was adjusted (as detailed below). After 1 to
3months, participants underwent a repeat BV measure-
ment. We compared the second value to the first in order
to judge whether an improvement in BV status occurred if
the dry weight prescription was changed, or to judge sta-
bility if it was not.
Blockade of iodine uptake by the thyroid gland was
achieved with a saturated solution of potassium iodide.
Participants took 130mg/day (1 drop of 1 g/ml potas-
sium iodide solution in 8 oz of water) the day prior to
the procedure and for 7 days after the BVA.
The study was approved by the local Institutional Review
Board and registered at ClinicalTrials.gov (NCT02717533).
Hemodialysis protocol
Hemodialysis was performed in accordance with stand-
ard, routine clinical care using the Phoenix® (Gambro,
Stockholm, Sweden) delivery system. The dialyzers used
were: Polyflux 210 (Gambro) or Rexeed 25SX (Asahi) as
per the patient’s prior prescription. Blood flow rates
were between 400 and 500 ml/min and a standard bicar-
bonate dialysate was used. The treatment time was indi-
vidualized depending on urea reduction rates and
ultrafiltration needs. Vital signs (including blood pres-
sure and heart rate) were recorded at the beginning, dur-
ing and at the end of the dialysis treatment as per
standard practice. Pre- and post- dialysis weights were
documented.
Information about intradialytic complications was col-
lected including: intradialytic hypertension (increase in
blood pressure ≥ 20mmHg), intradialytic hypotension
(systolic blood pressure < 90mmHg or decrease in blood
pressure ≥ 20 mmHg), tachycardia (heart rate 100/min,
or change > 30/min), cramping and, symptoms of vol-
ume depletion (dizziness, weakness, nausea, pre-syncope
or syncope) requiring medical intervention (interrupting
treatment, adjusting ultrafiltration or administration of
normal saline).
Blood volume analysis
BVA was performed using the BVA-100 device (Daxor
Corporation, New York, NY) applying the indicator dilu-
tion technique [30]. All BV measurements were made at
the VA-NYHHS nuclear medicine area within an hour of
ending the participants’ hemodialysis session. A blood
sample was collected at baseline for evaluation of per-
ipheral hemactocrit (Hct) and background radioactivity.
Then, 25 microCuries of Iodine-131 labeled albumin
were injected intravenously. After 12 min (in order to
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allow for proper mixing of radiolabeled albumin), 5 ml
blood samples were drawn at 6 min intervals for a total
of 6 samples. Hct was measured using HemataSTAT II®
Microhematocrit System (STI, Sanford, FL) for all sam-
ples then; the radioactivity level was measured using the
BVA-100 device. Linear regression for radioactivity level
of serial samples reflects the transudation of fluid from
the intravascular space to the interstitium and allows BV
and plasma volume (PV) determination by extrapolation
to volume of distribution at time zero.
BVA-100 device software calculates blood volume and
plasma volume according to the equations below:
PV ¼ 1000 x standard count‐baseline countð Þ
sample count‐baseline countð Þ
BV ¼ PV
1‐Hct x 0:99 x 0:91
peripheral Hct
whole body Hct
 
:
Estimated dry weight adjustment
Ideal BV is estimated from reference curves derived
from the standard Metropolitan Life Insurance Company
Desirable Weight tables in order to take into account
variability in body habitus [21, 30, 31]. For every patient,
BV was measured at baseline and compared to the cor-
responding ideal BV value. The difference between ideal
and measured BV allowed an estimation of the degree of
hypervolemia or hypovolemia at baseline, and guided the
prescription of EDW. The deviation from ideal BV was
considered statistically significant when it is larger than
±8% as supported by the manufacturer’s manual and
published literature [21]. The target EDW was defined
as the post-dialysis (post-HD) weight at which patient’s
post-dialysis BV would equal ideal BV. The patient’s
EDW prescription was changed in order to achieve this
target EDW. This definition assumes that ideal BV de-
fines euvolemia for each participant and that 1 L of BV
change would be equivalent to 1 kg of body weight. Sub-
sequent changes to the prescribed EDW were made ac-
cording to clinical indications, if needed.
Statistical analysis
Statistical analysis was performed using Mann-Whitney
U test, Wilcoxon signed rank test and Chi-square test
when comparing independent samples. Fisher’s exact
test was used when comparing 2 groups with less than 5
patients. For paired samples (comparing first to second
measurements), Signed rank test was used. Statistical
Fig. 1 Participant flow chart. BVA blood volume analysis, EDW estimated dry weight
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testing was computed using the Statistical Package for
the Social Sciences (SPSS 20 (SPSS Inc., Chicago). A
2-tailed p-value < 0.05 was considered to reach statistical
significance. Only patients who underwent both BVA
measurements were included in the statistical analysis.
Results
All patients, except for patient number 9, were men with
baseline demographics described in Table 1. At baseline,
only 3/10 patients were within 0.5 kg of prescribed
EDW. Based on BVA and comparison to “ideal” BV, 6 of
10 patients were euvolemic at baseline (Table 2). Only 1
was judged to be volume overloaded and 3 were consid-
ered volume depleted at baseline. Age, blood pressure
and heart rate were similar (p value > 0.05) for patients
that required a change in EDW compared with those
who did not.
As per protocol, we then changed the EDW prescribed
for the next hemodialysis for these 4/10 patients in order
to bring post-HD weight near target EDW (Table 3). We
also changed the EDW order for 2 patients who had BV
measures suggesting that, although deemed “euvolemic”,
they were further from ideal BV than might be consid-
ered desirable: patient 7 was above ideal BV by 8.0%,
and patient 11 was below ideal BV by − 6.2%. These
changes were consistent with the protocol and intended
to optimize BV. Hemodialysis was then performed with
the new target EDW, and BVA was repeated after a vari-
able interval of 1–3 months (Table 1).
The difference between measured BV and ideal BV did
not significantly differ from the first to the second BVA
measurement (P value 0.75). Patients remained in the
same volume status category whether their EDW was
changed according to BVA or not (P value 0.04). BV
remained unchanged at the second measurement (Cor-
relation coefficient 0.81, P value 0.004). Among patients
whose EDW was kept the same after the BVA measure-
ment, 4/5 were judged to be euvolemic at follow up. The
other patient, #2, had an increase in BV to 11% above
ideal BV, resulting in a diagnosis of mild volume
overload.
The difference between post-HD weight and pre-
scribed EDW was similar between patients who had
their EDW changed per protocol and those who did not
(P value 0.75). There was no linear relationship between
the change in absolute post-HD weight and change in
BV in our patient group (Fig. 2).
At baseline, the prevalence of intradialytic complica-
tions was low in both groups. No changes in the occur-
rence of intradialytic hypotension, hypertension or
cramps occurred in patients regardless of whether a
change in EDW was prescribed. Changing the EDW pre-
scription based on BVA did not affect the occurrence of
intradialytic complications. As expected from a prior re-
port [32], there was no apparent association between
cramping and iatrogenic volume depletion. Two out of
the 3 patients with cramps at a particular session were
considered euvolemic for that session while the 3rd pa-
tient was deemed volume overloaded.
Discussion
We previously demonstrated that BVA could be per-
formed in stable HD patients and could yield estimates of
BV and correlated with CLM-III readings [27]. Interven-
tional trials have also performed BVA to guide fluid man-
agement and diuresis in hospitalized patients [22, 25, 26].
This study is a pilot to determine feasibility, potential
benefits and reproducibility of volume status estimation
for outpatients with ESKD on hemodialysis. Despite its
feasibility, BVA did not lead to an improvement in
achieving euvolemia in our small patient population of
chronic HD patients. On the other side, BVA measure-
ments were stable when comparing the first and second
measurement; also, patients who did not have a change
in EDW per protocol remained euvolemic according to
the repeated measurement.
Flythe et al. recently reported an increased mortality
for patients who were more than 2 kg away from pre-
scribed EDW at the end of dialysis sessions [33]; in our
study we used a narrower margin and only considered 2
hemodialysis sessions. The difference between EDW and
post-HD weight was not affected by changing EDW
Table 1 Patient characteristics
Mean ± Standard Deviation
Age 40 ± 13
Years on dialysis 4.3 ± 3.2
Blood pressure (mmHg) 144/ 78 ± 28/ 10
Heart rate (beats/min) 82 ± 12
Deviation in BV (%) −2.7 ± 9.8
Time interval between the 2
measurements (days)
70 ± 29
N (%)
Gender (Male/Female) 9/1 (90/10)
Race
Black 7 (70.0)
White 1 (10.0)
Unknown / Not Reported 2 (20.0)
Ethnicity
Hispanic or Latino 2 (20.0)
NOT Hispanic or Latino 8 (80.0)
Was the EDW changed after initial BVA?
No 4 (40.0)
Yes 6 (60.0)
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based on BVA readings and our overall incidence of
complication was low as documented in Table 1..
Our protocol was based on the assumption that the
observed difference between measured and ideal BV
could be extrapolated to a desired change in weight.
Based on our data, it is not possible to validate our ini-
tial assumption that a change in target weight would
affect BV in a linear fashion (Fig. 2). Weight and BV
were even found to change in opposite direction in cer-
tain cases (Fig. 2). This can be partly explained by the
average of 70 days between both measurements, and also
by the fact that BVA measures intravascular volume but
not total ECV.
Our data are consistent with prior reports showing
small changes in BV measurements by BVA in patients
with heart failure who were admitted for diuresis despite
large changes in body weight upon hospital discharge
[26]. Previous BVA data in patients on HD also de-
scribed a wide variability of the percentage of total
weight loss that is in fact from the intravascular compo-
nent (54 to 99%) [27]. The heterogeneous source of fluid
loss can therefore explain the absence of a linear rela-
tionship when several patients are considered in this
study.
Our current observation is that despite the variability
in post-HD weights, BV measurements were reprodu-
cible over 1–3 months in patients on chronic
hemodialysis. Thus, a cross-sectional BV measurement
may provide information about chronic volume status
that is an important factor influencing morbidity in the
ESKD population [6, 11, 15, 34, 35]. This finding further
emphasizes the need to realize that a large proportion of
fluid removal occurs from interstitial ECV while intra-
vascular ECV appears to be more stable over time and
may require a longer-term strategy to be controlled.
Our study has several limitations related to the small
sample size and to the fact that participants were gener-
ally not far from what was judged to be a desirable or
ideal weight. The technique may be more useful for pa-
tients newly initiated on HD. BVA may also provide use-
ful information about intravascular ECV to guide
management in patients with intradialytic hemodynamic
instability.
The second BVA measurement occurred at variable in-
tervals after the first to suit patient and physician prefer-
ences. We viewed this as a pragmatic allowance given
that the patients were not unstable. The ideal time inter-
val between the initial reading and the follow up meas-
ure is currently indeterminate. BVA requires trained
personnel, equipment and availability of a nuclear medi-
cine facility (which are possible to obtain in the out-
patient setting). The measurement also requires patient
cooperation for a time consuming procedure and con-
sent to be subjected to low doses of radiation. Planning
Fig. 2 Change in measured BV between 1st and 2nd BVA (in %) according to change in measured post dialysis weight (in kg). Change in
measured BV(blood volume) (y-axis) is the difference between measured BV at the second BVA (blood volume analysis measurement) and the BV
measured at the first BVA. The change in post-HD (post-hemodialysis) (y-axis) weight equals the post-HD weight on the day of the second BVA
minus the post-HD weight on the day of the first BVA. Both the change in measured BV and the change in post-HD weights were calculated for
every patient. Linear regression was performed and shows no linear relationship between changes in post-HD weight and changes in measured
BV (coefficient of determination, r 2 = 0.08)
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measurements and repeating BVA should balance pa-
tient safety, resource allocation and stability of lean body
mass (i.e. non-volume-related body weight).
Non-invasive alternatives to BVA have been developed
for determination of volume status in hemodialysis pa-
tients. While BVA estimates the whole body’s intravascu-
lar BV, lung ultrasound evaluates pulmonary congestion
and cannot provide information about intravascular fluid
or other areas of interstitial fluid accumulation. Inferior
vena cava ultrasound measures central vasculature filling
and thus only intravascular volume. Bioimpedance spec-
troscopy (BIS) estimates all extracellular volume and
thus cannot appreciate intravascular and interstitial fluid
separately. BIS is a promising, non-invasive technique
and has been validated as an accurate estimator of extra-
cellular volume against dilution techniques [36, 37]. BIS
has been used during HD to with some success to
minimize hypotension [38] and improve blood pressure
control [8–10].
It is important to keep in mind that BIS and BVA
measure different volumes and may be different pieces
of the same puzzle to reach “euvolemia”. Many patients
with ESRD suffer from chronic edema and probing to
normalize their total ECV may lead to depletion of intra-
vascular ECV. BVA may be helpful in quantitatively as-
sess the intravascular fluid compartment in these
patients and establish an ideal rather than “dry” weight.
Many of our patients had a mild increase in BV from
ideal, between 1 to 11% (the normal range is up to 8%)
and did not have a high incidence of intradialytic
complications.
Conclusions
Our pilot study demonstrates that in a relatively clinic-
ally stable population, BV measurements are stable over
1–3 months. The reproducibility of BV measurements
despite changes in post-HD weight suggests that most of
the fluid removal in dialysis is ultimately pulled from the
interstitium rather than intravascular space. BVA may
therefore be used to assess chronic volume status rather
than acute changes in the ESKD population. Further
studies with a more diverse and larger sample popula-
tion may still be needed in order to further evaluate the
relationship between change in weight and change in BV
over time. We would look forward to an adequate ran-
domized controlled trial that would be powered to
evaluate changes in morbidity after altering EDW ac-
cording to BVA results and determine an
outcome-based target range for BV. Establishing an
outcome-based “normal range” for patients of
hemodialysis would make BVA a clinically useful test
and shift our goal from probing for “dry weight” to iden-
tifying clinically safe BV.
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